Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)

Eulàlia Genescà, Mireia Morgades, Celia González-Gil, Francisco Fuster-Tormo, Claudia Haferlach, Manja Meggendorfer, Pau Montesinos, Pere Barba, Cristina Gil, Rosa Coll, María-José Moreno, Daniel Martínez-Carballeira, Irene Garcia Cadenas, Susana Vives Polo, Jordi Ribera, José González-Campos, Marina Díaz-Beyá, Santiago Mercadal, Maria Teresa Artola, Antonia CladeraMar Tormo, Arancha Bermúdez, Ferran Vall-Llovera, Pilar Martínez-Sánchez, María-Luz Amigo, Silvia Monsalvo, Andrés Novo, Marta Cervera, Antonio García-Guiñon, Juana Ciudad Pizarro, José Cervera, Jesús María Hernández Rivas, Isabel Granada, Torsten Haferlach, Alberto Orfao, F Sole, Jose-Maria Ribera

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

14 Cites (Scopus)

Resum

The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corresponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying karyotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), independently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Additional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel targeted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.
Idioma originalEnglish
RevistaLeukemia Research
Volum109
DOIs
Estat de la publicacióPublicada - 2021

Fingerprint

Navegar pels temes de recerca de 'Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)'. Junts formen un fingerprint únic.

Com citar-ho